1. Home
  2. ADMA

ADMA

ADMA Biologics Inc

Logo ADMA Biologics Inc

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Founded: 2004 Country:
United States
United States
Employees: N/A City: RAMSEY
Market Cap: 1.4B IPO Year: N/A
Target Price: $7.88 AVG Volume (30 days): 2.6M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.13 EPS Growth: N/A
52 Week Low/High: $3.06 - $6.76 Next Earning Date: 05-08-2024
Revenue: $258,215,000 Revenue Growth: 67.59%
Revenue Growth (this year): 31.89% Revenue Growth (next year): 16.77%

Share on Social Networks: